Clinical Results

In clinical trials, the RD-X19 treatment device has demonstrated the potential to shorten disease duration through accelerated resolution of symptoms and reduced SARS-CoV-2 virus.

3 Phases Real-World Impact

Phase #1

Human Safety

This first-in-man (FIM) study evaluated the acute safety, tolerability, and acceptability of the investigational device among healthy volunteers.

Key points

  • No serious adverse events
  • Device acceptable

Phase #2


Two studies (Early Feasibility and Dose Ranging) evaluated safety and efficacy of the RD-X19 device in individuals with symptomatic COVID-19 in the outpatient setting.

Key points

  • Confirmed target dose
  • Identified patient population

Phase #3


A randomized, double-blind, sham controlled, efficacy and safety study of the RD-X19 device in individuals 40 years of age and older with Mild COVID-19 in the at-home setting.

Key points

  • Sustained symptom resolution
  • Time to negative test

Earn up to $1,080 in EmitBio’s Clinical Study.

EmitBio Inc. is a life science company developing breakthrough medical devices that change how the world treats respiratory infectious disease.

©2024 EmitBio

Privacy Policy